medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2022, Number 3

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2022; 20 (3)

Lineal erythematous painful plaque (LEPP) rule in herpes zoster infection: a simple clinical observation

Silva LE

Language: English
References: 22
Page: 318-322
PDF size: 414.84 Kb.


ABSTRACT

Herpes zoster, or shingles, is a localized disease characterized by unilateral radicular pain and a rash limited to the area of skin innervated by a single dorsal root or cranial sensory ganglion. Whereas varicella, or chickenpox, results from primary exogenous varicella-zoster virus (VZV) infection, herpes zoster is caused by reactivation of latent endogenous VZV. Early diagnosis of herpes zoster is characterized by: lineal, ererythematous, painful, plaque (LEPP rule) in the first 24 to 72 hours, it has a favorable impact on instituting early treatment, reduces the severity of the disease and prevents the appearance of postherpetic neuralgia. Four immunocompetent patients with positive LEPP rule are presented.


REFERENCES

  1. Hope-Simpson RE, The nature of herpes zoster: a long-term studyand a new hypothesis, Proc R Soc Med 1965; 58:9-20. Available at:http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1898279&blobtype=pdf. Accessed April 8, 2009.

  2. Head H and Campbell AW, The pathology of herpes zoster and itsbearing on sensory localisation, Brain 1900; 23:353-523.

  3. Gnann JW Jr and Whitley RJ, Herpes zoster [review], N Engl J Med2002; 347:340-6.

  4. Weller TH, Varicella and herpes zoster: a perspective and overview, JInfect Dis 1992; 166(suppl 1):s1-6.

  5. Preblud SR, Orenstein WA and Bart KJ, Varicella: clinical manifestations,epidemiology, and health impact in children, Pediatr Infect Dis1984; 3:505-9.

  6. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, HaywardAR et al., Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators. Varicella-zoster virus-specific immuneresponses in elderly recipients of a herpes zoster vaccine, J Infect Dis2008; 197:825-35.

  7. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LDet al., Shingles Prevention Study Group. A vaccine to prevent herpeszoster and postherpetic neuralgia in older adults, N Engl J Med 2005;352:2271-84. Available at: http://content.nejm.org/cgi/content/full/352/22/2271. Accessed April 8, 2009.

  8. Oxman MN, Clinical manifestations of herpes zoster. In: Arvin AM,Gershon AA (eds.), Varicella-zoster virus: virology and clinical management,Cambridge, England, Cambridge University Press, 2000, pp. 246-75.

  9. Cohen JI, Straus SE and Arvin AM, Varicella-zoster virus replication,pathogenesis, and management. In: Knipe DM, Howley PM (eds.), Fieldsvirology, 5th ed., Philadelphia, Pa, Lippincott Williams & Wilkins, 2007,pp. 2773-818.

  10. Hayward AR and Herberger M, Lymphocyte responses to varicellazoster virus in the elderly, J Clin Immunol 1987; 7:174-8.

  11. Gnann, Jr. JW, Varicella zoster virus: atypical presentations and unusualcomplications, J Infect Dis 2002; 186: S91-8.

  12. National Institute for Health and Clinical Excellence (nice), cks clinicalknowledge summaries, Shingles. Available in: www.cks.nice.org.uk. AccessedMar 2014.

  13. Dworkin RH, Johnson RW, Breuer J et al., Recommendations for themanagement of herpes zoster, Clin Infect Dis 2007; 44:S1-26.

  14. Chen N, Li Q, Yang J et al., Antiviral treatment for preventing postherpeticneuralgia, Cochrane Database Syst Rev 2014; 2:cd006866.

  15. Dworkin RH, Johnson RW, Breuer J et al., Recommendations for themanagement of herpes zoster, Clin Infect Dis 2007; 44:Suppl 1: S1.

  16. Wood MJ, Kay R, Dworkin RH et al., Oral acyclovir therapy acceleratespain resolution in patients with herpes zoster: a meta-analysis ofplacebo-controlled trials, Clin Infect Dis 1996; 22:341.

  17. Jackson JL, Gibbons R, Meyer G and Inouye L, The effect of treatingherpes zoster with oral acyclovir in preventing postherpetic neuralgia.A meta-analysis, Arch Intern Med 1997; 157:909.

  18. Tyring S, Barbarash RA, Nahlik JE et al., Famciclovir for the treatmentof acute herpes zoster: effects on acute disease and postherpeticneuralgia. A randomized, double-blind, placebo-controlled trial. CollaborativeFamciclovir Herpes Zoster Study Group, Ann Intern Med

  19. 1995; 123:89.19. Gnann JW Jr, New antivirals with activity against varicella-zoster virus,Ann Neurol 1994; 35 Suppl:S69.

  20. Beutner KR, Friedman DJ, Forszpaniak C et al., Valaciclovir comparedwith acyclovir for improved therapy for herpes zoster in immunocompetentadults, Antimicrob Agents Chemother 1995; 39:1546.

  21. Salvaggio MR and Gnann JW Jr, Drugs for herpesvirus infections ininfectious diseases, 4th ed., 2017.

  22. Yaldiz M, Solak B, Kara RO, Cosansu N and Erdem MT, Comparisonof famciclovir, valaciclovir, and brivudine treatments in adult immunocompetentpatients with herpes zoster, American Journal of Therapeutics2018; 25(6):e626-34.




2020     |     www.medigraphic.com